Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

J&J to submit NDAs for at least 10 new drugs by 2023

Written by: | no-reply@reuters.com | Dated: Wednesday, May 15th, 2019

 

Johnson & Johnson to submit applications for at least 10 new drugs by 2023

 

(Reuters) – Johnson & Johnson said on Wednesday it expected to file marketing applications for at least 10 new drugs between 2019 to 2023, to strengthen its pharmaceuticals unit which has been a major growth driver.

This is part of the healthcare conglomerate’s plan to deliver above-market growth through 2023 at its Janssen unit, it said. The plan comes ahead of J&J’s business review, scheduled later on Wednesday.

The company said it would discuss four medicines that are new to J&J’s pipeline of drugs at its review as well as therapeutic areas such as gene therapy and RNA therapeutics.

 

Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur

 

Reuters source:

https://www.reuters.com/article/us-johnson-johnson-outlook/johnson-johnson-to-submit-applications-for-at-least-10-new-drugs-by-2023-idUSKCN1SL1BM

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom